Table 2 HCC patients’ clinical informationa
From: Drug screening on digital microfluidics for cancer precision medicine
Patient # | Sex | Age | Immuno-suppressed | Metastasis | In-vitro effective drugs | In-vivo treated drugs | Group | Cancer recurrence |
|---|---|---|---|---|---|---|---|---|
1 | Male | 51 | N | N | – | – | Ctrl | N |
2 | Male | 69 | Y | Y | Lenvatinib | Lenvatinib | Pos | N |
3 | Male | 40 | N | N | – | – | Ctrl | N |
4 | Male | 69 | N | N | – | Corida + lenvatinib | – | – |
5 | Male | 67 | N | N | – | Atenolizumb + bevacizumab | – | – |
